Low‐density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia. (8th June 2020)

• Record Type: Journal Article
• Authors: Floeth, Matthias; Elges, Sandra; Gerss, Joachim; Schwöppe, Christian; Kessler, Torsten; Herold, Tobias; Wardelmann, Eva; Berdel, Wolfgang E.; Lenz, Georg; Mikesch, Jan‐Henrik; Hartmann, Wolfgang; Schliemann, Christoph; Angenendt, Linus
• Is Part Of: British journal of haematology. Volume 192:Number 3(2021)
• Page Start: 494
• Page End: 503
• Publication Date: 2020-06-08
• Subjects: acute myeloid leukaemia -- LDLR -- prognostic impact -- novel targets -- tissue microarray; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.16853
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: The low‐density lipoprotein receptor (LDLR) is a membrane receptor that mediates the endocytosis of low‐density lipoprotein (LDL). Uptake of LDL has been proposed to contribute to chemotherapy resistance of acute myeloid leukaemia (AML) cell lines in vitro . In the present study, we analysed LDLR expression and survival using bone marrow biopsies from 187 intensively treated patients with AML. Here, increasing LDLR expression was associated with decreasing overall (58·4%, 44·2%, and 24·4%; P = 0·0018), as well as event‐free survival (41·7%, 18·1%, and 14·3%; P = 0·0077), and an increasing cumulative incidence of relapse (33·9%, 55·1%, and 71·4%; P = 0·0011). Associations of LDLR expression with survival were confirmed in 557 intensively treated patients from two international validation cohorts. In the analytic and validation cohorts, LDLR expression remained associated with outcome in multivariable regression analyses including the European LeukemiaNet genetic risk classification. Thus, LDLR predicts outcome of patients with AML beyond existing risk factors. Furthermore, we found low expression levels of LDLR in most healthy tissues, suggesting it as a promising target for antibody‐based pharmacodelivery approaches in AML.